Biotechnology CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst – CymaBay Therapeutics (NASDAQ:CBAY), Gilead Sciences (NASDAQ:GILD) Read more
Biotechnology NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules – NexImmune (NASDAQ:NEXI) Read more
Biotechnology NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules – NexImmune (NASDAQ:NEXI) Read more